Prescribing a ketone-based diet to prevent or reduce the progression of age-related disease
Please leave the feedback on this idea
Originality
Is it original or innovative?
Feasibility
Is it feasible?
Necessity
Is it targeting an unsolved problem?
Conciseness
Is it concisely described?
Bounty for the best solution
Provide a bounty for the best solution
Bounties attract serious brainpower to the challenge.
[1]https://www.un.org/en/sections/issues-depth/population/
[2]https://www.un.org/en/sections/issues-depth/ageing/#:~:text=According%20to%20data%20from%20World,be%20aged%2065%20or%20over.
[3]White, M. C., Holman, D. M., Boehm, J. E., Peipins, L. A., Grossman, M., & Henley, S. J. (2014). Age and cancer risk: a potentially modifiable relationship. American journal of preventive medicine, 46(3 Suppl 1), S7–S15. https://doi.org/10.1016/j.amepre.2013.10.029
[4]McNally MA, Hartman AL. Ketone bodies in epilepsy. J Neurochem. 2012;121(1):28–35.
[5]Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum (Minneap Minn) [Internet]. 2013;19(June): 756–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 23739109
[6]McDonald, T., & Cervenka, M. C. (2018). Ketogenic Diets for Adult Neurological Disorders. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 15(4), 1018–1031. https://doi.org/10.1007/s13311-018-0666-8
[7]Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;45(6):1843–52.
[8]Nebeling, L.C., Miraldi, F., Shurin, S.B., Lerner, E., 1995. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. Journal of the American College of Nutrition 14: 202e208.
[9]Weber, D. D., Aminzadeh-Gohari, S., Tulipan, J., Catalano, L., Feichtinger, R. G., & Kofler, B. (2020). Ketogenic diet in the treatment of cancer - Where do we stand?. Molecular metabolism, 33, 102–121. https://doi.org/10.1016/j.molmet.2019.06.026
[10]Kudryavtseva, A. V., Krasnov, G. S., Dmitriev, A. A., Alekseev, B. Y., Kardymon, O. L., Sadritdinova, A. F., Fedorova, M. S., Pokrovsky, A. V., Melnikova, N. V., Kaprin, A. D., Moskalev, A. A., & Snezhkina, A. V. (2016). Mitochondrial dysfunction and oxidative stress in aging and cancer. Oncotarget, 7(29), 44879–44905. https://doi.org/10.18632/oncotarget.9821
[11]Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev [Internet]. Elsevier B.V.; 2009;59(2):293–315. https:// doi.org/10.1016/j.brainresrev.2008.09.002
[12]Taylor MK, Sullivan DK, Mahnken JD, Burns JM, Swerdlow RH. Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. Elsevier Inc.; 2018;4:28–36.
[13]Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, et al. Effects of β-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004;25(3):311–4.
[14]Ota M, Matsuo J, Ishida I, Hattori K, Teraishi T, Tonouchi H, et al. Effect of a ketogenic meal on cognitive function in elderly adults: potential for cognitive enhancement. Psychopharmacology (Berl)
[15]Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) [Internet]. 2009;6(1):31. Available from: http://nutritionandmetabolism. biomedcentral.com/articles/10.1186/1743-7075-6-31
[16]Rebello CJ, Keller JN, Liu AG, Johnson WD, Greenway FL. Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: A randomized controlled trial. BBA Clin. The Authors; 2015;3:123–5.
[17]Yin Y, Wang Z. ApoE and Neurodegenerative Diseases in Aging. Adv Exp Med Biol. 2018;1086:77-92. doi: 10.1007/978-981-13-1117-8_5. PMID: 30232753.
[18]Franceschi C & Campisi J (2014) Chronic inflammation(inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 69(Suppl 1), S4–S9.
[19]Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H,Rakugi H & Morishita R (2018) Source of chronicinflammation in aging. Front Cardiovasc Med 5, 12.
[20]Franceschi C, Garagnani P, Vitale G, Capri M &Salvioli S (2017) Inflammaging and ‘Garb-aging’.Trends Endocrinol Metab 28, 199–212
[21]Koppel SJ, Swerdlow RH. Neurochemistry International Neuroketotherapeutics: A modern review of a century-old therapy. Neurochem Int [Internet]. Elsevier Ltd; 2017; https://doi.org/ 10.1016/j.neuint.2017.05.019
[22]Cullingford TE. The ketogenic diet; fatty acids, fatty acidactivated receptors and neurological disorders. Prostaglandins Leukot Essent Fat Acids. 2004;70(3):253–64.
[23]Youm Y, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med [Internet]. Nature Publishing Group; 2015;21(3):263–9. https:// doi.org/10.1038/nm.3804
Please leave the feedback on this idea
Please leave the feedback on this idea
Please leave the feedback on this idea
Please leave the feedback on this idea
Please leave the feedback on this idea